Cortellis Deals Landscape


During the first quarter of 2016, Cortellis Competitive Intelligence had 1,011 new deals added as part of its ongoing coverage of pharmaceutical licensing activity. This was a slight decrease on the last quarter (Q4 2015: 1,075) but a significant increase on the same quarter for the previous year (Q1 2015: 826). This article will focus on highlighting a number of the most valuable and notable deals forged during the quarter, as well as a selection of deals from some of the most prolific deal makers. An update on milestone, options and terminated deals of significance will also be presented, along with an early outlook on the next quarter’s pharmaceutical licensing activity.

High-value deals: potentially worth approximately $0.5 billion or more
Approximately 37 high value new partnerships were entered into during this quarter. Of these, 15 could potentially generate $0.5 billion or more in revenues for their primary collaborators.

Baxalta moves into oncology through $3.48 billion Symphogen and Precision Biosciences’s transactions

Baxalta partnered with Denmark-based Symphogen for the development of immune-oncology compounds against six undisclosed checkpoint targets. The first program was planned to enter into phase I in 2017. Symphogen would assume preclinical and clinical development efforts of all programs until phase I, following which Baxalta might execute its exclusive right to opt-in for further development and commercialization. In exchange, Baxalta would pay Symphogen an upfront payment of $175 million, $1.6 billion in option and milestone payments, plus royalties.

Precision Biosciences was also selected by Baxalta to expand its anticancer portfolio. The companies agreed to collaborate on the development of allogeneic CAR T-cell therapies using Precision’s ARCUS genome editing technology against up to six oncology targets worldwide. The clinical studies were expected in late 2017. Precision would be responsible for preclinical and clinical development of the programs up to phase II, subsequently Baxalta might exercise its option to continue further development and commercialization. Precision also obtained a 50/50 co-development and co-promotion option right in the US. Precision got $105 million in upfront payment and Baxalta would pay milestone payments up to $1.6 billion, as well as royalties.

Roche Strikes 2.38 Billion Deals With Blueprint, C4 and Catalent For New Molecules....(Read more here)